News Breaks |
|
|
| January 18, 2013 |
| 14:21 EDT |  | LLY | Lilly drug chosen by U.S. researchers for Alzheimer's trial, Reuters says
Eli Lilly's (LLY) experimental Alzheimer's treatment solanezumab has been chosen for a federally sponsored trial that will explore whether the drug can slow or prevent Alzheimer's before the onset of serious symptoms, according to a Reuters report. Reference Link |
|
|
News For LLY From The Last 14 Days Check below for free stories on LLY the last two weeks. |
|
|
| May 21, 2013 |
| 07:24 EDT |  | LLY | Global Health Care to host a conference
 Subscribe for More Information |
|
| May 16, 2013 |
| 08:55 EDT | | LLY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| May 14, 2013 |
| 09:09 EDT |  | LLY | Eli Lilly announces CEO John Lechleiter recovering from surgery
Subscribe for More Information |
|
| 07:24 EDT | | LLY | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 10, 2013 |
| 11:48 EDT | | LLY | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| 08:02 EDT | | LLY | Eli Lilly's Enzastaurin Phase III study did not meet primary endpoint
Eli Lilly announced Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma. The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were consistent with previously disclosed studies. Lilly will stop development of enzastaurin, which is expected to result in a second-quarter charge to R&D expense of approximately $30M. The company's previously-issued financial guidance for 2013 remains unchanged. |
|
|
|
|
|
